FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes pill that also helps protect the heart from failure
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill approved by the FDA also lowers the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new diabetes pill that also helps protect the heart
The FDA has approved dapagliflozin tablets for two indications: to improve glycemic control in adults with type 2 diabetes mellitus, and to …
A new daily diabetes pill now approved by the FDA helps lower blood sugar and reduces the risk of heart failure hospitalization for adults w…
FDA Approves Dapagliflozin for Reducing Heart Failure Hospitalization Risk and Improving Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart
The FDA has approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and estab…
A new diabetes drug now helps lower blood sugar while also reducing the risk of heart failure hospitalization for adults with heart disease …
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes drug that also helps lower the risk of heart failure
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill now helps lower blood sugar and reduces the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Approves Dapagliflozin for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart from failure
The FDA has approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established ca…
FDA approves a diabetes pill that lowers blood sugar and reduces heart failure hospitalization for adults with type 2 diabetes and heart ris…
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug now protects the heart by lowering hospitalization risks for adults with type 2 diabetes and existing heart disease.
BP variability and pulse pressure associated with cognitive decline in type 2 diabetes patients
Blood pressure swings linked to thinking problems in people with type 2 diabetes
A secondary analysis of 9,586 patients with type 2 diabetes from the ADVANCE trial found that higher blood pressure variability and baseline…
For people with type 2 diabetes, big swings in blood pressure are linked to a higher risk of memory and thinking problems down the road.
Oral quadruple therapy reduces HbA more than metformin uptitration in type 2 diabetes on triple therapy
When three diabetes pills aren't enough, does adding a fourth help more than increasing metformin?
A 24-week, multicenter RCT in 193 adults with type 2 diabetes (HbA 7.0-9.0%) on triple oral therapy compared adding a fourth oral agent vers…
When three diabetes pills fail to control blood sugar, adding a fourth medication lowered HbA1c better than simply increasing the metformin …
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo.
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.
Resistance and interval training plus berry extract did not alter muscle AGEs in older adults
Exercise and berries did not change AGE levels in muscle tissue of older adults
A 12-week RCT in 41 healthy adults aged 55-70 found that supervised resistance and high-intensity interval training, preceded by 30 days of…
Exercise and berry supplements did not lower advanced glycation end-products in the muscle tissue of healthy older adults in this study.
Subgroup analysis finds tirzepatide superior to dulaglutide for HbA1c and weight in type 2 diabetes
For people struggling with diabetes on dulaglutide, could switching drugs help?
This subgroup analysis of a phase IV RCT examined adults with type 2 diabetes inadequately controlled on dulaglutide.
Switching from dulaglutide to tirzepatide led to greater drops in blood sugar and body weight for adults with type 2 diabetes after 40 weeks…
Tadalafil reduces some plasma neurodegeneration biomarkers in type 2 diabetes patients
Small study finds tadalafil may lower some Alzheimer's biomarkers in diabetes patients
A post-hoc analysis of a 6-week RCT in 15 individuals with type 2 diabetes found tadalafil reduced plasma amyloid-β 40, amyloid-β 42, and gl…
A small study suggests tadalafil lowers certain Alzheimer's-related blood markers in people with type 2 diabetes, though it did not change o…